The preliminary schedule and programme of the workshop are listed below. The programme will be updated according to the feedback from the speakers, so please watch this space.


Last updated: April 30, 2018


Wednesday 24 October, 12.00 - 13.00:

Registration and sandwich lunch


Wednesday 24 October, 13.00 - 18.00:



Wednesday 24 October, 18.00 - :

Welcome reception


Thursday 25 October, 8.45 - 18.00:

Talks and poster session 1


Friday 26 October, 9.00 - 17.30:

Talks and poster session 2


Friday 26 October, 19.00 - :

Conference dinner




Confirmed Speakers (presentation titles subject to change):



Developmental pathways implicated in the pathogenesis of germ cell malignancy


Walfred Tang (Cambridge, UK): Epigenetic dysregulation of primordial germ cells and gonocytes as a mechanism of transformation to germ cell neoplasia in situ.


Anne Jørgensen (Copenhagen, DK): The involvement of NODAL/Activin pathway in testicular dysgenesis and dysregulation of pluripotency in human fetal germ cells.


Rod Mitchell (Edinburgh, UK): Deregulation of human testicular development by endocrine disruptors; evidence from experimental studies. Implications for testicular cancer in humans?




Epidemiology and risk factors for testicular cancer


Jason K. Gurney (Wellington, New Zealand): Unexpected features of the epidemiology of testicular cancer among different populations in New Zealand.


Katherine McGlynn (Bethesda, MD, USA): Changing trends in the incidence of testicular cancer: are we close to an explanation of ethnic differences?


Ariana Znaor (Lyon, France): Global patterns and trends in testicular cancer incidence.




Genetic predisposition, genomic and epigenetic changes in testicular cancer


Kate Nathanson (Philadelphia, PA, USA): Novel testicular cancer predisposition loci begin to reveal possible mechanisms.


Maria Santa Rocca (Padua, Italy): Association between copy number variations and risk of testicular cancer.


Saud H. Aldubayan (Boston, MA, USA): Genomic changes during progression of testicular germ cell cancer


Anne Goriely (Oxford, UK): Spermatocytic tumours: what can this rare TGCT teach us about the fundamental processes operating in the adult male germline?


Leendert H. Looijenga (Rotterdam, the Netherlands): Clinical relevance of (epi)genetic changes during reprograming of GCNIS/seminoma to nonseminomas.




Paediatric germ cell tumours: New insights into the pathogenesis


Jason Heaney (Houston, TX, USA): Insights into malignant transformation of primordial germ cells from non-primate animal models.


James Amatruda (Dallas, TX, USA): Genomics of pediatric germ cell tumours.


Lindsay Frazier (Boston, MA, USA): Should there be a different therapeutic approach to pediatric vs. adolescent/young adult germ cell tumor patients?




Novel mechanisms and pathways possibly involved in germ cell cancer and male infertility


Ramsay J. McFarlane (Bangor, Wales, UK): Meiosis-like functions in oncogenesis.


Aspasia Ploubidou (Jena, Germany): Spindle misorientation in the aetiology of germ cell disorders, hypofertility and testicular germ cell cancer.


Robert S. Weiss (Durham NC, USA): A mouse model of malignant testicular cancer based on KRAS activation and PTEN inactivation.


Trine Haugen (Oslo, Norway): SPRY4 and SPRY4-IT1 as possible oncogenes in TGCT.


Hubert Schorle (Bonn, Germany): The plasticity of germ cell cancer and its dependence on the cellular microenvironment.


Joanna Selfe (London, UK): IGF1R signalling in primordial germ cells and testicular cancer.




Immunological aspects of testicular germ cell tumours


Michal Chovanec (Bratislava, Slovakia): Immune mechanisms and possible immune therapy in testicular germ cell tumours.


Kate Loveland (Clayton, VIC, Australia): Cytokins in testicular germ cell cancer.




Mechanisms and management of resistance to chemotherapy


Daniel Berney (London, UK): What is new in the latest WHO classification of testicular tumours and what else needs to be changed.


Carsten Bokemeyer (Hamburg, Germany): Clinical features and current treatment of refractory germ cell tumours.


Christoph Oing (Hamburg, Germany): Molecular basis of treatment resistance and potential therapeutic targets.




Early diagnosis and management of testicular cancer


Klaus-Peter Dieckmann (Hamburg, Germany): Detection of GCNIS using specific miRNA profiles.


Kristian Almstrup (Copenhagen, DK): Is it possible to detect GCNIS/early tumours in semen samples?


Gedske Daugaard (Copenhagen, DK): Risk factors predicting relapse of stage I testicular cancer undergoing surveillance.


Joerg Beyer (Bern, Switzerland): Risk classification in patients with disseminated disease.


Robert Hamilton (Toronto, Canada): Surgical treatment of disseminated GCTs – what is new and why?




Management of late effects in testicular cancer survivors


Jourik A. Gietema (Groningen, The Netherlands): Genetic susceptibility to late effects of chemotherapy in TGCT survivors.


Mikkel Bandak (Copenhagen, DK): Testicular function in long-term survivors of testicular cancer and the effects of androgen replacement therapy.


Jakob Lauritsen (Copenhagen, DK): Risk of cardio-vascular disease in long-term survivors of testicular cancer.


Michael Kreiberg (Copenhagen, DK): Quality of life in long-term survivors of testicular cancer.





Two poster sessions planned on Basic Aspects and Clinical Aspects (with guided tours).